What Ensysce Biosciences does

Ensysce Biosciences is a clinical-stage biopharmaceutical company developing abuse-deterrent and overdose-protected opioid prodrugs built on two proprietary technology platforms: TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance). TAAP chemically modifies active pharmaceutical ingredients into inactive prodrugs that only activate upon contact with trypsin in the small intestine, preventing activation via crushing, snorting, or injection. MPAR adds a trypsin inhibitor (nafamostat) that limits drug release when more than prescribed doses are consumed, providing oral overdose protection. The lead product PF614 is a TAAP oxycodone prodrug currently in Phase 3 clinical trials for severe post-surgical pain, with PF614-MPAR combining PF614 with nafamostat for overdose protection. The pipeline extends into TAAP amphetamine prodrugs (PF8001, PF8026) for ADHD and PF9001 for opioid use disorder.

The company pursues FDA approval under the 505(b)(2) NDA pathway with PF614 holding Fast Track designation and PF614-MPAR holding Breakthrough Therapy designation. Ensysce plans future commercialization through traditional pharmaceutical distribution channels (retail and hospital pharmacies) supported by manufacturing partnerships with Purisys (Noramco subsidiary) and Galephar. The company currently has no commercial revenue and funds operations through NIH/NIDA grants (over $34 million cumulatively) and dilutive equity financings. As of early 2026, the Board initiated review of strategic alternatives including potential partnerships, licensing arrangements, or asset sales. Ensysce faces going concern uncertainty and Nasdaq listing qualification challenges due to stockholders' equity deficiency.

Name

Ensysce Biosciences

Legal name

Ensysce Biosciences, Inc.

Website

https://ensysce.com

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

Ensysce Biosciences is a clinical-stage biopharmaceutical company developing abuse-deterrent and overdose-protected opioid prodrugs using proprietary TAAP and MPAR platforms, with lead candidate PF614 in Phase 3 trials for severe pain and no commercial revenue.

Ownership category

akta.pro rank

Product category

Pain Management Pharmaceuticals

NAICS

Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

Keywords

• Abuse-deterrent opioids
• Prodrug pharmaceutical development
• Overdose protection technology
• Opioid pain therapeutics
• Clinical-stage biopharmaceutical

Headquarters

HQ city

La Jolla

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pharmaceutical Product Sales: Once regulatory approval is obtained, Ensysce plans to commercialize its abuse-deterrent opioid products (PF614, PF614-MPAR) through traditional pharmaceutical sales channels. The company is currently in Phase 3 clinical trials with market entry anticipated within 18-24 months of trial initiation.
2. Technology Licensing: Ensysce offers out-licensing opportunities for its TAAP™ and MPAR® technologies to other pharmaceutical companies for product differentiation and market expansion. The company has over 100 issued patents globally to support licensing arrangements.
3. Grant Funding (Non-Dilutive): The company receives grant funding from NIH and NIDA to support clinical development of PF614-MPAR and other programs. Received $14 million NIH grant and $15 million NIH/NIDA award for opioid use disorder programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels10 records

Core offering

Ensysce Biosciences is a clinical-stage pharmaceutical company developing abuse-deterrent and overdose-protected opioid prodrugs using two proprietary technology platforms: TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance). Its lead candidate PF614 is in Phase 3 trials for severe and chronic pain, while PF614-MPAR combines the TAAP prodrug with the protease inhibitor nafamostat to deliver the first oral opioid with overdose protection and has received FDA Breakthrough Therapy designation.

Product overview

Ensysce Biosciences is developing a portfolio of abuse-deterrent and overdose-protected opioid prodrugs using two proprietary technology platforms: TAAP (Trypsin-Activated Abuse Protection) and MPAR (Multi-Pill Abuse Resistance). The lead product PF614 (TAAP oxycodone) is in Phase 3 clinical trials for severe pain. PF614-MPAR combines PF614 with nafamostat for overdose protection and has received FDA Breakthrough Therapy designation. The company is also developing PF8001/PF8026 (TAAP amphetamines for ADHD) and PF9001 (for opioid use disorder) using these platforms.

Differentiator

Problem solved

Functional benefit

Products and services

• PF614 An oxycodone-based prodrug built on the TAAP™ platform, designed to treat severe and/or chronic pain. It is chemically modified to be inactive until swallowed, when digestive enzymes in the small intestine release oxycodone, providing 12-hour pain relief with abuse-deterrent properties. Received FDA Fast Track designation.
• PF614-MPAR Combines PF614 with the trypsin inhibitor nafamostat to deliver both abuse resistance and overdose protection; positioned as the first oral overdose-protected opioid. Received FDA Breakthrough Therapy designation.
• PF9001 Lead clinical candidate for the treatment of opioid use disorder, using TAAP™ technology to provide reduced cardiovascular side effects and lower abuse potential.
• PF8001 Extended-release prodrug of amphetamine built on the TAAP™ platform, designed to improve safety and reduce abuse potential of ADHD medications.
• PF8026 Immediate-release prodrug of amphetamine built on the TAAP™ platform, intended for ADHD treatment with improved safety and reduced abuse potential.
• TAAP™ Technology Platform Proprietary prodrug technology platform offered for out-licensing to other pharmaceutical companies. Ensures opioids (or other oral drugs) are only activated when swallowed and contact trypsin in the small intestine, preventing abuse via snorting, injection, or chewing.
• MPAR® Technology Platform

Quantifiable outcome

• PF614 demonstrated bioequivalence to OxyContin 40mg when given as PF614 100mg in healthy subjects
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Purisys, LLC (subsidiary of Noramco, LLC)coreTechnology or Integration · 20 November 2025Manufacturing partnership supporting FDA-aligned commercial production strategy for PF614. Purisys, a subsidiary of Noramco, is providing manufacturing capabilities to support the company's pathway toward regulatory approval and commercial scale-up.
• GalepharcoreTechnology or IntegrationManufacturing partner engaged in production activities for PF614 alongside Purisys to ensure adequate commercial supply upon regulatory approval.

Scale indicators15 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Nektar Therapeutics: Nektar is a clinical-stage company exploring novel pain and CNS mechanisms with comparable small-cap, clinical-stage profile to Ensysce. Comparable in scale and capital markets dynamics if not in exact therapeutic focus.

Broad incumbents

• Mallinckrodt Pharmaceuticals: Mallinckrodt markets generic and branded opioids including abuse-deterrent oxycodone formulations, and has historically competed in the severe pain category. Represents a broader specialty pharma incumbent with overlapping opioid portfolio.
• Vertex Pharmaceuticals: Vertex is advancing suzetrigine (NaV1.8 inhibitor) and other non-opioid pain candidates, representing the most prominent emerging competitive threat to opioid-based pain therapies. While not directly competing on mechanism, both target the same severe pain prescribers and patient pool.
• Purdue Pharma: Purdue's OxyContin established the abuse-deterrent reformulated opioid category that PF614 seeks to disrupt. Although now in bankruptcy restructuring, Purdue remains a reference point for branded abuse-deterrent opioid commercialization.

Direct peers

• Collegium Pharmaceutical: Collegium markets Xtampza ER (abuse-deterrent oxycodone ER) and Nucynta (tapentadol), the closest direct competitors to PF614 in the abuse-deterrent opioid pain space. Both target the same severe/chronic pain prescriber base and pharmacy channels.
• Trevena: Trevena developed and commercialized OLINVYK (oliceridine), a branded opioid analgesic for moderate-to-severe acute pain in hospital settings. Comparable clinical-stage-to-commercial journey with a differentiated opioid mechanism.
• BioDelivery Sciences International: BDSI commercialized Belbuca, a buprenorphine-based pain product with abuse-deterrent properties, and was ultimately acquired by Collegium. Directly comparable as a small-cap abuse-deterrent opioid specialist targeting similar pain specialists.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

• Xx.com/EnsysceBio
• Facebookfacebook.com/ensyscebio
• LinkedInlinkedin.com/company/ensyscebio

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds18 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ensysce Biosciences